CannBioRx Life Sciences Corp (NASDAQ:ATNFW) — Market Cap & Net Worth
Market Cap & Net Worth: CannBioRx Life Sciences Corp (ATNFW)
CannBioRx Life Sciences Corp (NASDAQ:ATNFW) has a market capitalization of $4.30K ($4.30K) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31345 globally and #6013 in its home market, demonstrating a 4200.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CannBioRx Life Sciences Corp's stock price $0.43 by its total outstanding shares 9995 (9.99K). Analyse cash efficiency ratio of CannBioRx Life Sciences Corp to see how efficiently the company converts income to cash.
CannBioRx Life Sciences Corp Market Cap History: 2020 to 2025
CannBioRx Life Sciences Corp's market capitalization history from 2020 to 2025. Data shows growth from $3.30K to $4.30K (20.13% CAGR).
CannBioRx Life Sciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CannBioRx Life Sciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ATNFW by Market Capitalization
Companies near CannBioRx Life Sciences Corp in the global market cap rankings as of May 4, 2026.
Key companies related to CannBioRx Life Sciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CannBioRx Life Sciences Corp Historical Marketcap From 2020 to 2025
Between 2020 and today, CannBioRx Life Sciences Corp's market cap moved from $3.30K to $ 4.30K, with a yearly change of 20.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.30K | +4474.47% |
| 2024 | $93.95 | +123.81% |
| 2023 | $41.98 | -92.63% |
| 2022 | $569.72 | -91.86% |
| 2021 | $7.00K | +112.12% |
| 2020 | $3.30K | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of CannBioRx Life Sciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.30K USD |
| MoneyControl | $4.30K USD |
| MarketWatch | $4.30K USD |
| marketcap.company | $4.30K USD |
| Reuters | $4.30K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more